Deveining system and device

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Laitram, L.L.C. patent solves the following problem:

To prepare the shrimp, crawfish or other animals that have a root in the alimentary canal, it is often desirable to remove the vein. Current options for deveining shrimp include manual removal, which is inefficient and time-consuming, and automated device known in the art. With manual operation, a worker must perform a number of operations to partially or completely remove the shell from the meat of shrimp, and cut the meat with shrimp way desirable to the end user. Manual vein removal is relatively time consuming and thus lead to higher costs. Moreover, the recent contacts between the workers and the shrimp can lead to contamination of shrimps. Furthermore, the process results to be less than uniform depending on individual workers to perform the operation, and the diligence of the workers process shrimp.

Our analysis of this patent is as follows:

Laitram, L.L.C.’s patent US 9456617 B2 deals with Deveining system and device.
A deveining device efficiently removes the vein from the shrimp while preserving the meat of shrimp in both form and number. Deveining device consists of a channel that has a blade extending along a section of the canal to cut back on shrimp as it rolls through the channel to expose a vein. A low root remover severs the exposed vein from the shrimp body. Nozzles spray fluid channel to maintain shrimp by the way.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Head positioning device

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Vision Rt Limited patent solves the following problem:

Radiotherapy consists in projecting to a predetermined region of the body of a patient, a radiation beams to destroy or eliminate tumors present in it. The treatment is usually carried out each and repeatedly. In every medical intervention, the radiation source should be positioned with respect to the patient to Irradiate in selected regions with the highest possible accuracy to avoid shining adjacent tissues to harmful radiation beams.

Our analysis of this patent is as follows:

Vision Rt Limited’s patent US 9456947 B2 deals with Head positioning device.
A head positioning device for use in radio therapy described for positioning the head of a patient. The head positioning device comprising a head plate for supporting the head of a patient; a base plate for connection to a mechanical bed; and a head plate adjustment assembly connecting the head plate on the base plate where the head plate change society organized on various relative pitch, yaw and roll head plate relative to the base plate. The head positioning device arranged attached to a mechanical bed with the head plate and the head plate change society cantilevered end of the bed and the head plate change society suspended under the head plate and the base plate.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Dock-and-lock (DNL) vaccines for cancer therapy

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Ibc Pharmaceuticals, Inc. patent solves the following problem:

The present invention relates to the design and generation of dendritic cell-based, in vivo vaccine target for cancer therapy, such as multiple myeloma antigen. In preferred embodiments of the vaccine produced by the dock-and-lock (DNL) method, the effector moieties attached to anchor domain (AD) obtained from the AKAP protein dimerization and docking domain (DDD) moieties obtained of protein kinase a (PKA). DNL complexes generated when DDD moieties spontaneously dimerize and bind to an AD moiety, resulting in a complex with a 2: 1 stoichiometry between DDD and AD-related effectors. In more preferred embodiments, the effector moieties comprise a humanized anti-CD74 antibody, and a tumor-associated xenoantigen, such as a CD20 xenoantigen. In most preferred embodiments, the anti-CD74 antibody is an antibody hLL1. The DNL constructs for use in preparing pharmaceutical compositions, for the generation of vaccines against cancer, multiple myeloma (MM), and for the induction of an immune response against the tumor antigen expression cells, such as CD20 positive cancer cells in patients with multiple myeloma or other CD20-expressing cancers.

Our analysis of this patent is as follows:

Ibc Pharmaceuticals, Inc.’s patent US 9457072 B2 deals with Dock-and-lock (DNL) vaccines for cancer therapy.
The present invention concerns methods and compositions for the construction of the anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprising an antibody moiety that binds to dendritic cells, like an anti-CD74 antibody or antigen-binding fragment thereof, is included in an AD (anchor domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, where two copies of DDD moiety form a dimer that binds AD moiety, resulting in the formation of the DNL complicated. The anti-cancer vaccine DNL complex is able to induce an immune response against xenoantigen expressing cancer cells, as CD138negCD20 + MM stem cells and inducing apoptosis and inhibiting the growth of or eliminate cancer cells.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method for treating a CX3CR1-associated disease with CX3CR1-binding polypeptides

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Boehringer Ingelheim International Gmbh patent solves the following problem:

CX3CR1 is a G-protein coupled integral membrane proteins, which is a chemokine receptor. It is usually expressed in cells such as monocytes, dendritic cells and T cells associated with the initiation and progression of atherosclerotic plaque. It is upregulated in monocyte oxidized lipid and mediates migration of these cells to live within the plaques. The unique ligand fractalkine (FKN) expressed on the surface of vascular endothelial and smooth muscle cells in the wound where it modulates leukocyte adhesion. Fractalkine also released into circulation the proteolytic cleavage where it acts as a chemotactic agent.

Our analysis of this patent is as follows:

Boehringer Ingelheim International Gmbh’s patent US 9458235 B2 deals with Method for treating a CX3CR1-associated disease with CX3CR1-binding polypeptides.
The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acid encoding such polypeptides; to methods of preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and the use of such polypeptides or the composition, in particular for prophylactic, therapeutic and diagnostic purposes.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Jewelry enhancer

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Barbara Bixby patent solves the following problem:

This invention relates to jewelry chains, and especially, an enhancer to give the consumer the ability to quickly change the overall look and appearance of a necklace.

Our analysis of this patent is as follows:

Barbara Bixby’s patent US 9456667 B2 deals with Jewelry enhancer.
An enhancer for jewelry chains in which the enhancer connected to the lower end of a fiber surface and allow a plurality of lower grain included in each respective enhancer to allow the consumer to provide a plurality of ornamental show results for structures necklace. An alternative image to be used in a single enhancer for allowing a plurality of decorative elements like charm that more than one account.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Publication and interactive discussion engine driven by user-specified topic

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Hubub, Inc. patent solves the following problem:

Our analysis of this patent is as follows:

Hubub, Inc.’s patent US 9460208 B2 deals with Publication and interactive discussion engine driven by user-specified topic.
A backend system described in live web-accessible pages in with a user interface for interactive discussion to an end-user-specified subject. In one embodiment the system receives a subject from an end user, conducts a search related topics, displays thumbnails that represent things in the video, articles, tweets and photos from a multitude of sources throughout the internet on the subject, providing the user with an interface to choose the things that need to see a published subject pages, and built in one or more web-accessible pages with dynamic content that pertains to the subject with interactive ways to provoke participation of multiple users on the subject and content.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Human monoclonal antibodies to epidermal growth factor receptor (EGFR)

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Genmab A/S patent solves the following problem:

The EGF receptor (EGFR) is a 170 kDa type 1 transmembrane molecules. The expression found upregulated in many human tumors including carcinoma of the head and neck, breast, colon, prostate, lung, and ovaries. The kind of over-expression correlated with poor clinical prognosis (Baselga, et al (1994) Pharmac therapeut 64: ….. 127-154; Modjtahedi, et al (1994) Int J. Oncology 4: 277-296). Furthermore, his expression always accompanied by the production of EGFR ligands, TGF- and EGF among others, by EGFR-expressing tumor cells suggests that an autocrine loop participates in growth this cells (Baselga, et al. (1994) Pharmac therapeut 64: …. 127-154; Modjtahedi, et al (1994) Int J. Oncology 4: 277-296) .. Ali interaction between such EGFR ligands and EGFR therefore can inhibit tumor growth and survival (Baselga, et al (1994) Pharmac therapeut 64: 127-154).

Our analysis of this patent is as follows:

Genmab A/S’s patent US 9458236 B2 deals with Human monoclonal antibodies to epidermal growth factor receptor (EGFR).
Isolated human monoclonal antibody that specifically binds to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibody can be produced in a transfectoma or a non-human transgenic animals, for example, a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing VDJ recombination and isotype switch. also discloses pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas that produce human antibodies, and therapeutic and diagnostic methods using human antibody.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Fusobacterium polypeptides and methods of use

File for Quick & Easy Patent Protection with PowerPatent.

The Epitopix Llc patent solves the following problem:

Fusobacterium spp. program-negative, obligately anaerobic and pleomorphically rod-shaped bacteria that is responsible for a variety of necrotic infections in animals and humans (Langworth, Bacteriol. Rev. 41, 373-390 (1977)). Fusobacterium necrophorum classified into two types: F. necrophorum subsp. necrophoruin and F. necrophorum subsp. funduliforme and responsible for a number of clinical manifestations of various kinds of animals, such as cattle, sheep, and pigs which include; hepatic abscesses, foot rot, laminitis, purulent and interdigital dermatitis, contagious ecthyma, necrotic rhinitis, and necrotic laryngitis.

Our analysis of this patent is as follows:

Epitopix Llc’s patent US 9458204 B2 deals with Fusobacterium polypeptides and methods of use.
The present invention provides isolated polypeptides isolatable from a Fusobacterium spp. given also the present invention are compositions that include one or more of these polypeptides, and methods for making and methods for using the polypeptides.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Temporarily stiffened mesh prostheses

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Tyrx, Inc. patent solves the following problem:

Artificial implants such as meshes, combined mesh products or other porous prostheses are often used to provide a physical barrier between tissue types or additional strength to a physical defects in soft tissue. However, such devices commonly associated with post-surgical complications including post-implant infection, pain, excessive scar formation and shrinkage of the prosthesis or mesh. Excessive scar formation, limited patient mobility, and chronic pain is often attributed to the size, shape, mass and implant a variety of efforts made to reduce the amount of permanent formation. For example, lighter meshes using smaller fibers, greater besieged, and / or larger size pore as he meshes woven from the -resorbable and resorbable material usage to solve these problems.

Our analysis of this patent is as follows:

Tyrx, Inc.’s patent US 9457129 B2 deals with Temporarily stiffened mesh prostheses.
The present invention relates to medical prostheses and methods of manufacturing the devices. In particular, the prostheses temporarily stiffened meshes with particular coatings provide initial hardness and thus allow easier surgical management for the treatment or reconstruction of soft tissue defects. Preferred embodiments include surgical meshes coated with one or more biodegradable polymers that act as a hardening agent in the coat of filaments or fibers of the mesh in the temporary rise in points contact the filaments or fibers and / or by increasing the hardness of mesh at least 1.1 times its original hardness. In the minds of the invention may also provide relief from various post-operative complications associated with the implantation, insertion or surgical use. By including the biologically active agents and / or drugs in the coating, the devices provide Branch Tomato for relief and side effects or complications associated with the operation or use of prostheses generalized.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method and apparatus for dynamically processing an electromagnetic beam

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The At&T; Intellectual Property I, L.P. patent solves the following problem:

The increasing use of mobile personal devices, for example, cell phone, smart phone, and others, which dramatically increases network traffic. For example, all one billion people worldwide Internet users with a large part of this population access to the Web through their mobile phones. Moreover, the nature of the mobile phone customer changed in recent years. The number of users access media-rich data and social networking site on mobile personal devices have risen dramatically. For example, the average owner of a Smart phone transaction is many times the amount of data than did the first Smart phone users. Therefore, there is a need to always grow network capacity to accommodate the ever increasing traffic.

Our analysis of this patent is as follows:

At&T; Intellectual Property I, L.P.’s patent US 9461361 B2 deals with Method and apparatus for dynamically processing an electromagnetic beam.
A method and apparatus for processing a terahertz frequency electromagnetic beam that signifies. For example, the method receives the terahertz frequency electromagnetic beam through a metamaterial having a plurality of addressable magnetic elements, where a resonant frequency of each of the plurality of addressable magnetic elements are able programmably changed by a change, and stimulate selectively a subset of the plurality of addressable magnetic elements to manipulate terahertz frequency electromagnetic beam.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.